



607 14th Street, N.W.  
Suite 800  
Washington, D.C. 20005

Telephone (202) 783-6040  
Facsimile (202) 783-6031  
www.rfem.com  
info@rfem.com

June 3, 2015

VIA EMAIL

Doug Dixon  
Hueston Hennigan LLP  
620 Newport Center Drive, Suite 1300  
Newport Beach, CA 92660

Re: In re Amgen Inc. Securities Litigation, Case No. 07-cv-2536 PSG (PLAx)  
(C.D. Cal.)

Dear Mr. Dixon,

Thank you for your letter of May 29.

I must say I am appalled that Amgen is continuing its efforts to harass Paul Goldberg, an award-winning journalist, for his work in writing a story about a clinical trial concerning one of Amgen's products that revealed that Amgen's product was leading to treatment failure. But let's deal with the specifics of your letter.

1. I'm glad you are not "seek[ing] at this time the production of unpublished documents" since as I have previously informed you, Mr. Goldberg does not have any such unpublished documents because, to the extent any non-privileged documents ever existed, such documents are likely amongst those that The Cancer Letter turned over to the Sub-committee on Oversight and Investigations of the House Committee on Energy and Commerce in 2007.
2. I am glad that you are "not seek[ing] at this time discovery of the specific identities of confidential sources", because, as I have previously told you, you will not get them. And if you seek to get them, we will seek and obtain sanctions against your client.
3. The information that you say you do want demonstrates precisely why you are not entitled to Mr. Goldberg's deposition under well-established law that requires, inter alia, that the information you seek be "crucial" to your claims. See, e.g., *NLRB v. Mortensen*, 701 F. Supp. 244, 248 (D.D.C. 1988). You identify only two items you say you are seeking. First, you wish

G. Franklin Rothwell  
(1928-2011)

E. Anthony Figg  
Harry F. Manbeck, Jr.  
George R. Repper  
Steven Lieberman  
Joseph A. Hynds  
Martin M. Zoltick  
R. Danny Huntington  
Joo Mee Kim  
Richard Wydeven  
Sharon L. Davis  
Robert B. Murray  
Jeffrey L. Ihnen  
Brian S. Rosenbloom  
Jason M. Shapiro  
Brian A. Tollefson  
C. Nichole Gifford  
R. Elizabeth Brenner-Leifer  
Nancy J. Linck, Ph.D.  
Sharon E. Crane, Ph.D.  
Lisa N. Phillips  
Steven P. Weilhrouch  
Robert P. Parker  
Jenny L. Colgate

Leo M. Loughlin  
Monica Chin Kitts  
Michael V. Battaglia  
Seth E. Cockrum, Ph.D.  
Derek F. Dahlgren  
Michael H. Jones  
Jennifer P. Nock  
Rachel M. Echols  
Brett A. Postal  
Chen Li  
Jennifer B. Maisel  
Soumya P. Panda  
Jason M. Nolan, Ph.D.  
Aydin H. Harston, Ph.D.  
Daniel R. McCallum  
Abdul Q. Basit  
Thomas C. Chen  
Peter J. Park\*  
Longhao Wang\*  
Mark T. Rawls\*  
Sarah M. Cork, Ph.D.\*  
Nechama E. Potasnick\*  
Dennis Ostrovsky, Ph.D.\*


\*Not a member of the D.C.  
Bar. Practice limited to patent,  
trademark and copyright  
matters and cases in federal  
courts.

Of Counsel  
William N. Hughet  
Mary Frances Love

to ask how and when Mr. Goldberg learned about the DAHANCA 10 results on which he reported in the article. Presumably, you have the article. If you do not, here is another copy. The date of publication of the article is on the article. He learned about the study within a few days of publication. From whom he learned that is confidential and will not be disclosed. Second, you state that you are entitled to know how and when the article was publicly disseminated. The article was publicly disseminated on the date that it was published—a date you have, and presumably have had, for several years. It was publicly disseminated to The Cancer Letter's subscribers by mail and email, as our Rule 45 document response explained. You are not entitled to, and you will not be given, information about The Cancer Letter's subscriber list.

I trust this ends the matter. If it does not, please advise me in writing promptly so that we may file an appropriate motion.

Very truly yours,



Steven Lieberman

cc: Jenny Colgate